Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies

REFERENCES

• Voena C, Chiarle R. Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016;21:125–133.
   PubMed Web of Science ®Google Scholar
• Huillard O, Bakalian S, Levy C, et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer. 2014;50(3):638–648. doi:10.1016/j.ejca.2013.10.016.
   PubMed Web of Science ®Google Scholar
• Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–574. doi:10.1093/annonc/mdv623.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2016;27(7):1362. doi:10.1093/annonc/mdw141.
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol. 2015;33(28):3193–3198. doi:10.1200/JCO.2015.60.8448.
   PubMed Web of Science ®Google Scholar
• Common terminology criteria for adverse events (CTCAE), version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Updated 2017.
   Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. https://www.sciencedirect.com/science/article/pii/S0002939405004071.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918. doi:10.1016/S1470-2045(15)00083-2.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. doi:10.1056/NEJMoa1414428.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792. doi:10.1200/JCO.2015.66.1389.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835. doi:10.1056/NEJMoa1709030.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Oweira H, Petrausch U, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017;17(4):387–394. doi:10.1080/14737140.2017.1296765.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;JCO2017776385. doi:10.1200/JCO.2017.77.6385.
   Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):z. doi:10.1186/s40425-017-0300-z.
   Google Scholar
• Mori S, Kurimoto T, Ueda K, et al. Optic neuritis possibly induced by Anti-PD-L1 antibody treatment in a patient with non-small cell lung carcinoma. Case Rep Ophthalmol. 2018; 9(2):348–356. Published Jul 20, 2018. doi:10.1159/000491075.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamasaki O. Vogt-koyanagi-harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2017;5(5):694–700. doi:10.1002/ccr3.911.
   PubMed Web of Science ®Google Scholar
• Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288–294. doi:10.1097/CCO.0000000000000296.
   PubMed Web of Science ®Google Scholar
• Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep. 2012;6(4):423–426. doi:10.1097/ICB.0b013e31824f7130.
   PubMedGoogle Scholar
• Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol. 2015;133(8):965–967. doi:10.1001/jamaophthalmol.2015.1128.
   PubMed Web of Science ®Google Scholar
• Crews J, Agarwal A, Jack L, Xu D, Do DV, Nguyen QD. Ipilimumab-associated retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):658–660. doi:10.3928/23258160-20150610-10.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Inomata H, Rao NA. Vogt-koyanagi-harada syndrome. Surv Ophthalmol. 1995;39(4):265–292. [pii]. doi:10.1016/S0039-6257(05)80105-5.
   PubMed Web of Science ®Google Scholar
• Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in vogt-koyanagi-harada disease. Br J Ophthalmol. 1996;80:1002–1008.
   PubMed Web of Science ®Google Scholar
• Sugita S, Sagawa K, Mochizuki M, Shichijo S, Itoh K. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with vogt-koyanagi-harada disease. Int Immunol. 1996;8:799–803.
   PubMed Web of Science ®Google Scholar